低分子量ヘパリン
参考資料

↑  Weitz JI; Weitz, Jeffrey I. (1997). “Low-molecular-weight heparins”. N Engl J Med 337 (10):  688–98. doi:10.1056/NEJM199709043371007. PMID 9278467.
1 2 3  “Production and chemical processing of low molecular weight heparins”. Seminars in Thrombosis and Hemostasis 25 Suppl 3:  5–16. (1999). PMID 10549711.
↑  “Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines”. Chest 141 (2 Suppl):  e24S–43S. (2012). doi:10.1378/chest.11-2291. PMC 3278070. PMID 22315264. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3278070/.
↑  Michael D Randall; Karen E Neil (2004). Disease management. 2nd ed. London: Pharmaceutical Press. 186.
↑  “Archived copy”. 2012年7月7日時点のオリジナルよりアーカイブ。2010年2月7日閲覧。
↑  Lim, W; Dentali, F; Eikelboom, JW; Crowther, MA (2 May 2006). “Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.”. Annals of Internal Medicine 144 (9):  673–84. doi:10.7326/0003-4819-144-9-200605020-00011. PMID 16670137.
↑  Garcia, DA; Baglin, TP; Weitz, JI; Samama, MM; American College of Chest, Physicians (February 2012). “Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.”. Chest 141 (2 Suppl):  e24S–43S. doi:10.1378/chest.11-2291. PMC 3278070. PMID 22315264. http://journal.publications.chestnet.org/article.aspx?articleid=1159423.
1 2 3  “Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence)”. International Angiology : A Journal of the International Union of Angiology 25 (2):  101–61. (June 2006). PMID 16763532.
↑  Kelton, J.G. (2002-03). “Heparin-induced thrombocytopenia: an overview” (英語). Blood Reviews 16 (1):  77–80. doi:10.1054/blre.2001.0189. https://linkinghub.elsevier.com/retrieve/pii/S0268960X01901894.
↑  “Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials”. Archives of Internal Medicine 167 (22):  2423–30. (December 2007). doi:10.1001/archinte.167.22.2423. PMID 18071163.
1 2  Jeske W, Walenga J, Fareed J. Differentiating between the Low-Molecular-Weight-Heparin used for VTE treatment and prophylaxis. Thromb Clin. 2008;2(3)
↑  enotes.com > Encyclopedia of Nursing & Allied Health > Coagulation Tests Retrieved on April 5, 2010
1 2 3 4  massgeneral.org > Heparin Antifactor Xa Assay Archived 2009-08-08 at Archive.is Page Updated: September 18, 2009
↑  European Pharmacopedia Commission (October 1991). “LOW MOLECULAR MASS HEPAFUNS”. Pharmeuropa 3:  161–165.
↑  Gray, Elaine; Mulloy, Barbara; Barrowcliffe, Trevor (2008). “Heparin and low-molecular-weight heparin” (英語). Thrombosis and Haemostasis 99 (11):  807–818. doi:10.1160/TH08-01-0032. ISSN 0340-6245. http://www.thieme-connect.de/DOI/DOI?10.1160/TH08-01-0032.
↑  Xu, Y.; Masuko, S.; Takieddin, M.; Xu, H.; Liu, R.; Jing, J.; Mousa, S. A.; Linhardt, R. J. et al. (2011). “Chemoenzymatic Synthesis of Homogeneous Ultralow Molecular Weight Heparins”. Science 334 (6055):  498–501. Bibcode: 2011Sci...334..498X. doi:10.1126/science.1207478. PMC 3425363. PMID 22034431. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425363/.
↑  WHO Working Group on Biological Standardization of Unfractionated Heparin, WHO Headquarters, Geneva, Switzerland, 7–8 September 1999
↑  EMA/CHMP/BMWP/118264/2007. Guideline on non-clinical andclinical development of similar biological medicinal products containing Low-molecular-weight-heparins. March 2009.
↑  Nightingale, S. L. (1993). “The US Food and Drug Administration (FDA) alert”. JAMA 270 (14):  1672. doi:10.1001/jama.270.14.1672. PMID 8411485.
IdoA(2S)のアンヒドロマンノースは、アンヒドロマンニトールに還元される。
UA(2S)-GlcNS(6S)